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David Ezra18, Stefano Fazi19, Richard J. FitzGerald20, Laura M. Gargan7,
Susana P. Gaudêncio21, Nadica Ivošević DeNardis22, Danijela Joksimovic13,
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Hanna Mazur-Marzec26, Alexia Massa-Gallucci27, Mohamed Mehiri28,
Søren Laurentius Nielsen29, Lucie Novoveská30, Donata Overlingė23,
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Marine organisms produce a vast diversity of metabolites with biological activities
useful for humans, e.g., cytotoxic, antioxidant, anti-microbial, insecticidal, herbicidal,
anticancer, pro-osteogenic and pro-regenerative, analgesic, anti-inflammatory, anti-
coagulant, cholesterol-lowering, nutritional, photoprotective, horticultural or other
beneficial properties. These metabolites could help satisfy the increasing demand for
alternative sources of nutraceuticals, pharmaceuticals, cosmeceuticals, food, feed,
and novel bio-based products. In addition, marine biomass itself can serve as
the source material for the production of various bulk commodities (e.g., biofuels,
bioplastics, biomaterials). The sustainable exploitation of marine bio-resources and
the development of biomolecules and polymers are also known as the growing
field of marine biotechnology. Up to now, over 35,000 natural products have been
characterized from marine organisms, but many more are yet to be uncovered, as
the vast diversity of biota in the marine systems remains largely unexplored. Since
marine biotechnology is still in its infancy, there is a need to create effective, operational,
inclusive, sustainable, transnational and transdisciplinary networks with a serious and
ambitious commitment for knowledge transfer, training provision, dissemination of
best practices and identification of the emerging technological trends through science
communication activities. A collaborative (net)work is today compelling to provide
innovative solutions and products that can be commercialized to contribute to the
circular bioeconomy. This perspective article highlights the importance of establishing
such collaborative frameworks using the example of Ocean4Biotech, an Action within
the European Cooperation in Science and Technology (COST) that connects all and any
stakeholders with an interest in marine biotechnology in Europe and beyond.
Keywords: marine biotechnology, marine natural products, blue growth, marine biodiversity and chemodiversity,
responsible research and innovation, stakeholder engagement, science communication, sustainability
INTRODUCTION
During four billion years of evolution in the ocean, marine
organisms have evolved in their environment to biosynthesize
a plethora of biopolymers and biomolecules. These include the
unique secondary metabolites that are produced in response to
environmental stimuli. They play important biological roles in
improving competitiveness, providing chemical defense against
predators or competitors and facilitating reproductive processes.
These biomolecules are not always essential for the growth and
development of the organism, but they are important for the
survival and well-being in its environment. Furthermore, some
compounds such as marine enzymes have properties essential
for industrial applications like thermostability or tolerance to a
diverse range of pH and salinity conditions. These properties
are being utilized in various industries such as in the food,
animal feed, leather, textile and horticulture industries, and
in bioconversion and bioremediation processes (Rao et al.,
2017). Marine biotechnology appeared in the 1960s and 1970s
when scientists realized the potential of living organisms and
their natural products for industrial exploitation (Dias et al.,
2012). Initially, the investigation of marine ecosystems relied
on the easily accessible organisms like corals and sponges as
well as macroalgae that have high biomass levels and were
representative of targeted ecosystems (Greco and Cinquegrani,
2016). Therefore, most of the known natural products deriving
from the marine environment were initially isolated from macro-
organisms. On realizing that marine microbial biodiversity is
vast, largely underexplored and unexploited, the application
of marine microbial biotechnology aiming to valorize marine
resources is a natural step forward in the development of the
biotechnology sector.
For a long time, it has been considered that only around
1% of the whole marine microbial population could be cultured
under laboratory conditions (Vartoukian et al., 2010). However,
recent findings suggest the percentage of culturable microbial
population is higher; an estimated 13–78% of genera are cultured,
depending on the environment (Lloyd et al., 2018). For example,
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environments with high human engagement and disease-
driven research benefit from greater culturing effort (Lloyd
et al., 2018; Steen et al., 2019). Since many cells in non-
human environments belong to novel phyla, new culturing
approaches and innovations will increase the percentage of
uncultured microbes (Steen et al., 2019). Culture-independent
methods using omics approaches are nowadays used to detect
microorganisms that are yet uncultured. These methods include
high-throughput sequencing, metagenomics, transcriptomics,
proteomics, metabolomics, and bioinformatics resources for
the identification of organisms and elucidation of metabolic
pathways responsible for production of chemical compounds,
as well as DNA-based or heterologous expression systems.
Microbial identification is only an initial step and additional
research is essential to develop cultivation techniques to
obtain the necessary biomass in a sustainable manner. Next,
biochemical and genetic engineering methods are required for
the production of high quantities and quality of proteins, marine
oils and other secondary metabolites of interest. Figure 1
provides a schematic representation of parameters that should
be considered for the whole bioprospecting process, starting
from the selection of marine organisms, for their cultivation
prior to their utilization for the biosynthesis of high-value bio-
components and for investigation of their biological potential in
various industries.
Natural products are currently the most common source of
therapeutic agents. The World Health Organization estimates
that approximately 80% of the world’s population uses remedies
based on natural products to treat their basic health problems.
Over 35,000 bioactive compounds have been isolated and
chemically characterized from marine organisms since the 1960s
(Lindequist, 2016). While before 1985 less than 100 natural
products were discovered annually, in the late 1990s, this
number rose to over 500 new products discovered yearly
up to over 1,000 since 2008, mainly due to the advances
in analytical methods (Lindequist, 2016; Carroll et al., 2019).
The application of new dereplication strategies using mass
spectrometry (MS) and the use of high-resolution Nuclear
Magnetic Resonance (NMR) spectrometers with cryoprobes have
enabled the discovery of new natural products even at the
nanomole scale (Klitgaard et al., 2014). The most common
approach used for the discovery of new marine bioactive
chemical entities involves the screening of crude extracts or
partially purified fractions of similar polarities against selected
test organisms or therapeutic targets, followed by the purification
and the structure elucidation of the active ingredients. The
purification of metabolites is usually performed by means of
chromatographic separation techniques combined with high-
resolution MS based approaches that allow a rapid and accurate
identification of the molecular mass and formulae of bioactive
compounds. These methods are becoming a gold standard for
the rapid and reliable dereplication of natural product extracts
or fractions (Gaudêncio and Pereira, 2015).
The unique structural architecture and broad range of
activities exhibited by marine metabolites have caught the
attention of the scientific community. This has resulted in
the development of research programs promoting innovation
and industrial uptake along with the creation of new jobs
and of a competitive environment for biotechnology-
oriented enterprises as stated in the Blue Growth Strategy
of the European Union (EU). This orientation is in line
with the strategy for “A sustainable bioeconomy for
Europe: strengthening the connection between economy,
society and environment” which is a 2018 update from
the original 2012 Bioeconomy Strategy by the European
Commission (EC). The strategy aims to create a more
innovative, resource-efficient and competitive society
that will reconcile drug discovery and food security
with the sustainable and economically viable use of





There are two sustainability levels that must be considered
to effectively implement marine biotechnology in practice: (i)
environmental and (ii) supply sustainability. (i) Environmental
sustainability tackles the main sources of marine biomass
which come either from species harvested in nature or from
those that can be cultivated. It is especially relevant when
wild stocks are the only source of supply and they are over-
harvested, or where targeted marine species are rare, in the
deep, or difficult to re-sample. The harvesting/sourcing of any
target species should thus not threaten marine biodiversity
and the future availability of target species. To minimize
the environmental impact, the biotechnology community
should consider valorizing side and waste streams and co-
products, target sustainably cultured marine organisms
and those that are sufficiently productive to supply specific
high added-value biomolecules. (ii) Sustainable supply of
biomolecules represents key bottlenecks, as they are usually
present in trace amounts. To guarantee a sustainable sourcing
and production of target compounds, biologically active
molecules or whole organisms should therefore be considered
in a life cycle assessment and a multi-risk environmental
analysis context. This will attain a global evaluation including
environmental, health and economic aspects for both the
biological (sourcing) and technical (supplying) cycle. Industrial
symbiosis and circular economy approaches must therefore
be applied to find sustainable ways for utilization of marine
bioresources (blue growth) using green production techniques
that economize on exhaustible resources (green growth,
Rodrik, 2014).
Industry
Marine biotechnology generates various products and services,
from the production of biofuels, food, feedstuffs and products
for use in agriculture (high-volume, low-value, and low-risk
products), to the discovery of new biomaterials, cosmetics,
nutraceuticals and pharmaceuticals (low-volume, high-value and
high-risk products). Research and development investments for
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FIGURE 1 | Schematic representation of a bioprospecting protocol for the extraction of valuable bioactive compounds from marine organisms (adapted from Chen
et al., 2017).
the discovery of marine-derived drugs entail high levels of
capital expenditure and risk tolerance, as they require the use
of state-of-the-art infrastructures and many years of basic and
applied research (Figure 2). Despite some limitations, there are
successful examples, as to date there are ten approved drugs,
one example being trabectedin (ET-743), a product isolated
from a Caribbean sea squirt Ecteinascidia turbinata, which
is used for the treatment of advanced soft tissue sarcoma.
This product first reached the market in 2007, after 20 years
of research (Cuevas and Francesch, 2009). In practice, out
of every 2,500 analogs from the marine environment that
enter preclinical testing, only one may be safe and effective
enough to reach clinical use (Gerwick and Fenner, 2013).
There is a collaboration and communication gap between raw
ideas and materials and their potential laboratory innovation
and commercialization (Datta et al., 2014). This is being
tackled by adopting three different strategies. (i) Firstly, by
stimulating public-private partnerships in consortia that apply
for research and innovation funding (such as Horizon 2020
and Horizon Europe, Europe’s biggest research and innovation
funding resource). (ii) Another alternative are the business
incubators (such as Rocket57 in Northern Europe), think
tanks or stakeholder events that are often regionally financed
to answer strategic regional developmental priorities and
present a contact point for joining researchers, small and
medium enterprises, industrial representatives and investors. (iii)
Financial stimulation of networking activities (the example of
COST Action Ocean4Biotech is presented in the next chapter of
this article). The global marine biotechnology market is expected
to reach ∼$6.4 billion by 20251 and it currently represents
only ∼1% of the whole biotechnology market. Noteworthy,
the oceans cover over 70% of the Earth’s surface and contain
an estimated 25% of the world’s species (Mora et al., 2011),
of which most are unknown and undervalorized. Hence, the
marine biotechnology market is expected to expand at a much
higher pace (Figure 2) when high-throughput techniques and
the collaboration between industry, science, general public and
policy makers will be routinely used. The predominant players in
the European marine biotechnology consist of some 140 micro
SMEs (estimated by Ecorys, 2014) and academia that lack the
financial stability necessary for sustained and long-term cutting-
edge research.
Scientific Community
To fully explore the ocean and its biota, the current screening
and/or cultivation approaches of marine organisms of interest
for biotechnological applications need to be optimized (Figure
2). High-throughput techniques produce vast amounts of data
and can uncover the biodiversity and the metabolic potential
of marine organisms. Hence, knowledge on data management,
processing and data analysis to maximize the quality and quantity
1https://www.smithers.com/resources/2015/oct/global-market-for-marine-
biotechnology
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FIGURE 2 | Major prerequisites for the establishment of sustainable actions in
marine biotechnology.
of resulting information needs to be advanced. Experts from the
field of statistics, bioinformatics and chemometrics are essential
in biotechnology research groups nowadays and their pipelines
and databases should be integrated, harmonized and publicly
available to prevent duplication of efforts, reduce the overall costs
and support the discovery process.
General Public
While the world population is rising and is expected to
reach over 8.5 billion by 2030, bioresources and available
areas for cultivation and manufacture are declining. Hence,
there is a growing demand for additional sources of food,
drugs, and chemicals (Figure 2). Marine biotechnology
has the potential to mitigate these needs both by
increasing the current production and by introducing new
products in the food, feed, pharmaceutical, nutraceutical,
healthcare, welfare, biomaterials, and energy sectors.
Nowadays, consumers expect innovative, efficient, safe,
sustainable, ethical, financially, and environmentally friendly
solutions. We need to raise public awareness and improve
communication to a broad audience regarding the benefits
of marine biotechnology products to gain consumers’
interest in eco-friendly products that meet high standards
of sustainability.
Policy Makers
Some national, regional and global strategies and guidelines
are already in place to recommend investment into marine
biotechnology and stimulate networking and transdisciplinary
collaboration at the international level (Figure 2). These
include the United Nations (UN) sustainable development
goals2, national and EU legislation that must be developed
and harmonized. The UN Convention on the Law of the
Sea3 sets the rules for the exploitation, conservation and
management of living marine resources. The Nagoya Protocol
on Access to Genetic Resources and Benefit Sharing provides
a legal framework aimed at creating transparency for those
interested in the production and exploitation of genetic
materials. Marine biotechnology development needs also to
comply with the Habitats Directive (92/43/EEC) on the
conservation of natural habitats and of wild fauna and flora,
the Marine Strategy Framework Directive (MSFD) (2008/56/EC,
CD 2017/848) establishing a framework for community action
in the field of marine environmental policy, the EU Water
Framework Directive – WFD (Directive 2000/60/EC), and
the Maritime Spatial Planning Directive (2014/89/EU) for the
planning of multiple uses of the maritime and coastal areas.
Biomolecules and their production processes must also comply
with specific regulations related to the targeted application
(e.g., EU 2015/2283 Novel Foods and Ingredients, EC No
1223/2009 Cosmetic Regulation, EC No 1924/2006 Nutrition and
Health Claims, EC No 1907/2006 REACH Regulation, among
others). The widespread acceptance and certification of these
novel compounds is a rigorous and time-consuming process
where legislative documentation might need updating as novel
compounds are being identified. It is thus necessary to encourage
collaboration among scientists and policy makers, as outlined
during the UNESCO High-Level Conference on the Ocean
Decade (2018). Moreover, intellectual property strategies need to
be established and agreed upon to conduct research in accordance
with ethical recommendations for bioprospecting in the open
ocean and beyond the national jurisdictions covered by the
Nagoya protocol.
THE ESTABLISHMENT OF A
COLLABORATIVE NETWORK AS A
SOLUTION FOR ADVANCING MARINE
BIOTECHNOLOGY: COST ACTION
Ocean4Biotech
Efficient and sustainable exploitation of the ocean’s potential
is possible only if industrial actors, researchers, the general
public, policy makers and environmental experts work
together. This direct interaction among different stakeholders
across different countries is not always possible and limited
programs have been supported until today that allow a
minimal direct transdisciplinary interaction (see more in
Supplementary Table S1).
From this viewpoint, the EU COST program that was
established in 1971 represents an excellent opportunity for
the creation of research networks on diverse topics, called
COST Actions. These networks offer an open space for
collaboration among stakeholders across Europe (and beyond),
2https://sustainabledevelopment.un.org/
3https://www.un.org/depts/los/convention_agreements/texts/unclos/unclos_e.pdf
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thereby catalyzing research advancement and innovation4. One
of the recently approved Actions is CA18238 – European
transdisciplinary networking platform for marine biotechnology
(Ocean4Biotech)5. The motivation behind creation of this
network is included in the SWOT analysis (see Supplementary
Table S2 and the discussion therein). Ocean4Biotech is an
international, unique and inclusive network that gathers experts
from transdisciplinary fields of exact and natural sciences, social
sciences and humanities, giving the Action participants the
opportunity to work together and share their experiences creating
a spill-over effect to foster marine biotechnology and bioeconomy
in a sustainable way. Ocean4Biotech will apply the Responsible
Research and Innovation Roadmap (Theodotou Schneider, 2019)
involving scientists, citizens, policy makers and industry in the
co-creation of knowledge and in the establishment of sustainable
collaborative networks.
Notably, Ocean4Biotech builds upon existing knowledge from
current and past projects and initiatives (see Supplementary
Table S1). It aims to establish strong collaborations to avoid
the duplication of efforts. The difference between Ocean4Biotech
and the current and past efforts is this Action is envisaged
as a “connecting-the-dots” funnel initiative that will gather
scientists and professionals from all areas related to the
marine biotechnology field. This enables a wider approach
aiming to facilitate the circular economy in the marine
biotechnology sector. Researchers from all fields and levels
of expertise relevant to marine biotechnology will have the
opportunity to participate in the Action and will be included
in knowledge exchange activities (between the scientific fields
as well as within, e.g., senior-to-junior knowledge transfer),
establishing new collaborations and having an opportunity
for career advancement. The developments from this COST
Action can impact the industrial sector, and in turn will most
likely influence governance boards. However, the efforts of
Ocean4Biotech to establish connections between its members
and linkages with other initiatives will not be possible without
proactive science communication, extensive dissemination along
with active engagement and outreach activities. Efficient
communication will enable informing on the activities and
objectives of the Action and will attract researchers to prepare
and initiate new collaborations that will span beyond the lifetime
of Ocean4Biotech.
HOW WILL Ocean4Biotech FOSTER
ADVANCES IN THE FIELD OF MARINE
BIOTECHNOLOGY?
There are five general objectives within the Ocean4Biotech
COST Action:
(1) Description of marine biodiversity. Knowledge of
marine biodiversity is still limited. Moreover, there is a large
interregional variability in species distribution and in their
taxonomic knowledge. The lack of experts in marine species
4https://www.cost.eu/who-we-are/about-cost/
5https://www.ocean4biotech.eu/
taxonomy, duplicates/redundancies/inconsistencies in the
primary nucleotide databases, lack of type species and polyphyly
of traditionally established taxa result in many misidentified
or unidentified species/strains (many of which hold great
potential for biotechnological applications). These are also
important challenges to marine natural product programs.
Hence, human resources, research effort, time and cost-efficient
methods are needed to overcome the current gap in knowledge
on biological and chemical diversity in marine ecosystems.
These may be addressed by high-throughput methods that
facilitate the discovery, classification and supply of organisms.
However, high-throughput methods for biodiversity monitoring
have not been routinely adopted and the methodology for
biodiscovery is often not standardized. In fact, bioinformatics
pipelines and big data analyses are changing the landscape
for marine biotechnology, as around 18,000 new species are
uncovered yearly6. Ocean4Biotech will propose operating
procedures for uncovering the biodiversity using high-
throughput methods, such as DNA barcoding approaches
(Leese et al., 2016). These methods can then be combined
with a more quantitative assessment by in situ hybridization
techniques that allow the quantification and localization
of specific microbial clusters within the environmental
matrices. Such biodiversity assessment provides crucial
information for subsequent monitoring and exploitation
of marine organisms. The environmental impacts of such
biological prospecting are considered minimal at the early
stages of sampling, where the size of samples collected is
small. Moreover, the standardization of the biodiscovery
process is necessary as chemodiversity, even in the same
taxa, greatly varies along geographical and environmental
gradients, as well as seasonally and timely along the life
cycle of organisms.
(2) Natural product discovery is a process involving
separation techniques in parallel with biological screening,
followed by structure elucidation of the pure bioactive
metabolites. If the target compound from a given species
shows biotechnological potential, scale-up production and
supply will certainly increase the environmental impact.
However, the organic synthesis of the compound (although
time-consuming and expensive) and/or production of the
compound of interest using biological synthesis generally
overcome the need for repeated collection and over-exploitation
of the natural ecosystem. Therefore, Ocean4Biotech will build
a compendium of pipelines, i.e., methods and procedures,
detailed on a case study basis, starting from the creation
of marine biorepositories, the identification of the collected
species using integrative systematics, screening for specific
bioactivities for selected industries, identification of the
bioactive metabolites and their sustainable production,
business plan development, marketing strategy, where legal
and ethical aspects to be considered along with adherence
to strict guidelines for protection of the environment
and sustainability. These pipelines will serve as guidelines
and tutorials for future product development and will
6https://www.eurekalert.org/pub_releases/2018-05/scoe-elt051718.php
Frontiers in Marine Science | www.frontiersin.org 6 May 2020 | Volume 7 | Article 278
fmars-07-00278 May 12, 2020 Time: 16:14 # 7
Rotter et al. Marine Biotechnology Collaborative Network
enable the transfer of knowledge between disciplines. These
pipelines will highlight the complementary transdisciplinary
aspect of marine biotechnology and as a link with other
sectors of biotechnology. According to the principles
sustainability the supply chain decision-making will require
the inclusion of social and economic aspects together
with environmental aspects. Thus, the Action will apply an
integrated framework for Life Cycle Sustainability Assessment
(LCSA). Wherever possible, it will combine physical LCA
considering different environmental impact categories (e.g.,
climate change, eutrophication or acidification) at different
life-cycle levels (partial LCA) with social LCA (SLCA)
and Life Cycle Costing (LCC), based on UNEP/SETAC
guidelines. The approach used in this Action will build
on existing models (Perez-Lopez et al., 2018). It will also
follow the methodological framework for conducting
LCA as outlined by the International Standards Authority
(ISO) 14040 series.
(3) Sharing infrastructure. There is an increasing need to
create a bridge between research and innovation capabilities from
the academia and business sectors. This includes the availability
of the research infrastructure, thereby providing access to a
range of new tools and facilities to allow marine biotechnology
to thrive. Many of the tools and techniques used in marine
biotechnology are widely used in other areas of science and
technology. Engaging in collaborative research projects is one
way of providing access to these facilities and encouraging
multidisciplinary research. Ocean4Biotech will enable the diverse
actors to share their expertise and infrastructure, mostly through
short-term scientific missions and new collaborative activities.
Preference will be given to users from the less research-
intensive countries7 or early career investigators that need access
to state-of-the-art analytical equipment, microbial cultures or
screening facilities.
(4) Responsible Research and Innovation. The ocean should
be monitored, valorized and governed in a sustainable manner
to generate the maximum benefit to science and society but
limiting the negative footprints on the marine environment.
This will be addressed within the Action by adopting the
Responsible Research and Innovation (RRI) concept, which is
based on six pillars.
(i) Ethics. We are all responsible for the stability and resilience
of the Earth systems (Barbier et al., 2018). Accordingly, ethical
issues and challenges will be identified, addressed and used
to advocate for protection of marine ecosystems and promote
responsible resource management and environmental policies
together with societal awareness.
(ii) Open access. To efficiently co-create knowledge and
capitalize from previous research, it is vital to consider
transparency, efficiency, traceability, access to data, reciprocal
relations, biosafety, nature conservation and transfer of
knowledge to third countries.
(iii) Gender equality will be promoted throughout the Action
by empowering especially early career and female colleagues to
7https://www.cost.eu/who-we-are/cost-strategy/excellence-and-inclusiveness/
apply for managerial roles and in the future establish and lead
consortia for valorization of marine biotechnology products.
(iv) Governance. Although the marine biodiversity has no
borders, access to natural resources is framed under the
Convention of Biological Diversity, promoting the conservation
of biodiversity, the sustainable use of biological entities and
their fair and equitable sharing. The latter is also covered in
the Nagoya Protocol, which provides a legal framework for the
fair and equitable sharing of benefits arising from the use of
genetic resources which may sometimes delay or block certain
research activities.
(v) Public engagement. Action participants will employ
communication tools and different activities to further inform
legislative authorities, researchers and industry with the aim of
facilitating the regulatory requirements that are sometimes a
bottleneck to transnational collaboration.
(vi) Science education. We will focus many of our activities
into education of the next generation of researchers (i.e.,
early career investigators), with a special focus on the
countries that are less research intensive, i.e., the so-
called inclusiveness target countries8. These countries have
developed their national strategic priorities in the frame of
the EU Smart Specialization Strategy (S3), aiming to ensure
a balanced development between regions8. Since marine
biotechnology, including its products and applications, is
well represented in all national S3 priorities, the timing is
perfect to develop capacity-building educational opportunities
that span beyond the traditional academic curricula. We
will enable closing the educational gaps in three ways.
(i) By short term scientific missions, which are mobility
activities that involve a direct hands-on interaction and
experience abroad. (ii) By offering financial opportunities
for active participation in conferences that target any of the
marine biotechnology related topics. (iii) Importantly, our
trainings and workshops, that will be publicly promoted,
will cover topics that integrate academy, technological
centers and industry (as also promoted by the EuroMarine
Working Group, 2019). By offering multidisciplinary
skills, this strategy will avoid the risk of training a
marine-related workforce that the market may not absorb
(EuroMarine Working Group, 2019).
(5) Knowledge co-creation and integration. (i) The
Action will be geographically inclusive as it will produce
an open-access database of exploitable species for marine
biotechnology in the Ocean4Biotech participating countries. In
addition to the World Register of Marine Species (WoRMS9),
this Action participants will focus on those species with
putative biotechnological potential. (ii) The Action will be
inclusive in the biological sense and include species regardless
of the kingdom (from bacteria and algae to zooplankton
and other species that are suitable for exploitation). (iii)
Methodologically, the participants will integrate all levels
of the biotechnological pipeline; from bioprospecting
to cultivation, biological screening, compound isolation
8https://ec.europa.eu/jrc/en/research-topic/smart-specialisation
9http://www.marinespecies.org/
Frontiers in Marine Science | www.frontiersin.org 7 May 2020 | Volume 7 | Article 278
fmars-07-00278 May 12, 2020 Time: 16:14 # 8
Rotter et al. Marine Biotechnology Collaborative Network
and optimization of the isolation process, and structure
elucidation. (iv) This is a truly transdisciplinary Action,
integrating expertise and including experts from various
fields: marine (micro)biology, chemistry, food science,
agriculture, pharmacology, medicine, environmental protection,
engineering, energy, data science, omics techniques, statistics,
law, policy making, economy, business planning, and more.
The network will transfer knowledge from traditional academic
institutions to exploitation industries leading to the elaboration
of ecosystem services linked to policy makers’ priorities, citizens,
industry and SMEs.
CONCLUSION
This Ocean4Biotech COST Action will contribute to
the implementation of the Bioeconomy Strategy and
the European Green Deal10. It will also mainstream the
responsible research and innovation principles among the
scientific and industry communities to foster the interaction
between marine scientists and other marine biotechnology
stakeholders, including the general public. Such interaction
will be multidirectional rather than top–down and co-
creative instead of just being introduced by the authorities
and/or knowledge holders. Outreach and communication
activities will provide information to the broad community
and improve their capacity to understand the challenges
and opportunities to make appropriate decisions in the
field of marine biotechnology. An inclusive, integrative
approach is essential to catalyze the expansion of marine
biotechnology in Europe and worldwide and to finally
harvest the products of this promising field of research.
Finally, the establishment of interdisciplinary connections and
collaborations during Ocean4Biotech’s lifetime will not only
lead to future research collaborations that include industrial
representatives as well, but also provide establishment of
communication channels with policymakers, governments, and
other stakeholders, including the public. This will eventually
enable beneficial social and environmental impacts that will
ultimately contribute to a more efficient and sustainable use of
marine bioresources.
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